top of page
Search

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects with Solid Tumors

Phase 1 trial, 230 patients

Trial opened April 2024 in Australia

Expanded to US Locations in September 2024

 

“Brief Summary

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.”

 

NOTE: All interventional trials involve risk. 

So please consult with your oncology tem as well as ask questions of the trial researchers.

 


TRIAL NCT06326411

 

July 2024 Research paper



The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers

 

 

March 2024

FDA Clears IND for NST-628 for Advanced Solid Tumors With RAS-MAPK Mutations


 

 

Genentech_Logo.png_dark blue text that reads, "Genetech." Gray italicized text that reads, "a member of the Roche Group."
Blue capitalized text on a gray background. Text reads, "Amgen."
Dark blue text on top of sea foam text. Text reads, "Verastem Oncology."
Black capitalized text that reads, "Revolution Medicine."
bottom of page